登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
Synergistic Effects of PD-1 Antibody and Chemotherapy/Targeted Therapy Followed by Surgery-centric Local Treatment in Patients With Limited-metastatic Gastric Cancer
ClinicalTrials.gov 上登记的一项胃癌开放试验,由复旦大学附属中山医院牵头,本站收录的另外 0 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT06468280,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 6
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(6 项)收起清单
18 岁 至 79 岁;性别:不限
登记记录的入选字段
Pathologically confirmed gastric adenocarcinoma or gastroesophageal junction adenocarcinoma (Siewert II or III only) with known PD-L1 expression status.
入选标准第 2 条
Prior PD-1/PD-L1/PD-L2 or other T-cell-targeting therapy.
排除标准第 10 条
ECOG score ≤2, no surgical contraindications.
入选标准第 6 条
History of previous malignancies or concurrent other malignancies, with the exception of completely resected basal cell or squamous cell skin cancer, superficial bladder cancer, carcinoma in situ of the cervix or breast, and other tumors with no recurrence for at least 5 years.
排除标准第 5 条
HBsAg-positive with HBV DNA ≥500 IU/mL.
排除标准第 18 条
Positive HIV antibody.
排除标准第 19 条
Fertile women with a negative urine or serum pregnancy test and agreement to use effective contraception during the study and for 180 days after the last dose. Non-sterilized men must also agree to use effective contraception.
入选标准第 10 条
Pregnancy, lactation, or planning for pregnancy.
排除标准第 17 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);化验:血常规、肝肾功能;影像与可测量病灶。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06468280,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Men or women aged 18-79. Pathologically confirmed gastric adenocarcinoma or gastroesophageal junction adenocarcinoma (Siewert II or III only) with known PD-L1 expression status. Gastric cancer with proficient mismatch repair (pMMR) or microsatellite stability (MSS) as determined by immunohistochemistry or NCI-recommended microsatellite markers. Primary gastric cancer lesions are resectable, with limited distant metastases meeting the either of the following criteria: (1) condition (a) only; (2) any single condition from (b), with or without (a). No previous anti-tumor treatments. ECOG score ≤2, no surgical contraindications. Life expectancy ≥ 3 months. Physical condition and organ function suitable for major abdominal surgery. Willingness and ability to comply with the study protocol. Fertile women with a negative urine or serum pregnancy test and agreement to use effective contraception during the study and for 180 days after the last dose. Non-sterilized men must also agree to use effective contraception. Signed informed consent with an understanding that patients can withdraw anytime.排除标准:Exclusion Criteria:
Inability to tolerate oral chemotherapy. Primary gastric lesion confined to the mucosa or submucosa with isolated ovarian metastasis. Central nervous system metastasis and/or carcinomatous meningitis. Allergy to any components of the study medication. History of previous malignancies or concurrent other malignancies, with the exception of completely resected basal cell or squamous cell skin cancer, superficial bladder cancer, carcinoma in situ of the cervix or breast, and other tumors with no recurrence for at least 5 years. Uncontrolled pleural effusion, pericardial effusion, or ascites. Weight loss ≥20% within two months before enrollment. Upper gastrointestinal obstruction or physiological dysfunction. Previous cytotoxic chemotherapy, radiotherapy, immunotherapy, or curative surgery. Prior PD-1/PD-L1/PD-L2 or other T-cell-targeting therapy. Systemic steroid or immunosuppressant use within 14 days before enrollment. Live vaccine within four weeks prior to enrollment. Uncontrolled systemic disease. Active or past autoimmune diseases that may recur. Severe chronic infections or active infections requiring systemic antibacterial, antifungal, or antiviral treatment. History of lung disease. Pregnancy, lactation, or planning for pregnancy. HBsAg-positive with HBV DNA ≥500 IU/mL. Positive HIV antibody. Conditions that may impact study compliance or participation.
引自 ClinicalTrials.gov, NCT06468280, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06468280,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。